These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
89. A review of second-line chemotherapy and prognostic models for disseminated germ cell tumors. Voss MH; Feldman DR; Bosl GJ; Motzer RJ Hematol Oncol Clin North Am; 2011 Jun; 25(3):557-76, viii -ix. PubMed ID: 21570609 [TBL] [Abstract][Full Text] [Related]
90. High-dose etoposide: from phase I to a component of curative therapy. Wolff SN; Hainsworth JD; Greco FA J Clin Oncol; 2008 Nov; 26(33):5310-2. PubMed ID: 18838698 [No Abstract] [Full Text] [Related]
91. Diagnosis and treatment of patients with testicular germ cell cancer. Hartmann JT; Kanz L; Bokemeyer C Drugs; 1999 Aug; 58(2):257-81. PubMed ID: 10473019 [TBL] [Abstract][Full Text] [Related]
92. Hematopoietic growth factors and treatment of testicular cancer: biological interactions, routine use and dose-intensive chemotherapy. Bokemeyer C; Kuczyk MA; Köhne H; Einsele H; Kynast B; Schmoll HJ Ann Hematol; 1996 Jan; 72(1):1-9. PubMed ID: 8605273 [TBL] [Abstract][Full Text] [Related]
93. Treatment intensification in disseminated germ-cell tumors. Beyer J; Bokemeyer C; Schmoll HJ; Siegert W World J Urol; 1994; 12(4):207-13. PubMed ID: 7820143 [TBL] [Abstract][Full Text] [Related]
94. VP 16 plus ifosfamide plus cisplatin as salvage therapy in refractory testicular cancer. Einhorn LH Cancer Chemother Pharmacol; 1986; 18 Suppl 2():S45-50. PubMed ID: 3815718 [TBL] [Abstract][Full Text] [Related]
95. In vitro pharmacodynamic evaluation of VP-16-213 and implications for chemotherapy. Wolff SN; Grosh WW; Prater K; Hande KR Cancer Chemother Pharmacol; 1987; 19(3):246-9. PubMed ID: 3581418 [TBL] [Abstract][Full Text] [Related]
96. Etoposide. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in combination chemotherapy of cancer. Henwood JM; Brogden RN Drugs; 1990 Mar; 39(3):438-90. PubMed ID: 2184009 [No Abstract] [Full Text] [Related]
97. Cisplatin/etoposide/ifosfamide stepwise dose escalation with concomitant granulocyte/macrophage-colony-stimulating factor for patients with far-advanced testicular carcinoma. Harstrick A; Schmoll HJ; Bokemeyer C; Metzner B; Illiger HJ; Berdel W; Ostermann H; Manegold C; Räth U; Siegert W J Cancer Res Clin Oncol; 1991; 117 Suppl 4():S198-202. PubMed ID: 1665492 [TBL] [Abstract][Full Text] [Related]
98. High-dose VP-16-213 monotherapy for refractory germinal malignancies: a phase II study. Wolff SN; Johnson DH; Hainsworth JD; Greco FA J Clin Oncol; 1984 Apr; 2(4):271-4. PubMed ID: 6368760 [TBL] [Abstract][Full Text] [Related]
99. High-dose VP-16-213 and autologous bone marrow transplantation for refractory malignancies: a phase I study. Wolff SN; Fer MF; McKay CM; Hande KR; Hainsworth JD; Greco FA J Clin Oncol; 1983 Nov; 1(11):701-5. PubMed ID: 6366131 [TBL] [Abstract][Full Text] [Related]